Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

UTHR Relative to the S&P 500

UTHR Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the United Therapeutics Corp. (NASD:UTHR) seasonal charts above shows that a Buy Date of October 24 and a Sell Date of January 15 has resulted in a geometric average return of 9.95% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 17 of those periods. This is a very good rate of success and the return outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 1.13% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company’s therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company’s sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

To download UTHR seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: UTHR